Saturn V Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Saturn V Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$83M	Buy	4,624,101 +274,216	+6%	+$4.24M	11.91%	1
2026 Q1	$60.5M	Sell	4,349,885 -146,602	-3%	-$2.06M	10.95%	2
2025 Q4	$54.3M	Sell	4,496,487 -108,391	-2%	-$1.47M	9.97%	2
2025 Q3	$62.6M	Buy	4,604,878 +1,344,308	+41%	+$12.7M	13.72%	2
2025 Q2	$20.9M	Buy	3,260,570 +834,134	+34%	+$4.06M	8.47%	3
2025 Q1	$8.59M	Buy	2,426,436 +1,537,363	+173%	+$5.47M	4.33%	11
2024 Q4	$3.36M	Buy	+889,073	New	+$4.18M	1.32%	19
2024 Q1	–	Sell	-1,099,268	Closed	-$16.2M	–	23
2023 Q4	$16.2M	Buy	1,099,268 +213,125	+24%	+$3.27M	6.19%	7
2023 Q3	$16.2M	Buy	+886,143	New	+$18.7M	6.79%	6

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Saturn V Capital Management's AMLX Position: Q2 2026 in Review

Saturn V Capital Management increased its Amylyx Pharmaceuticals (AMLX) stake by 6.3% in Q2 2026, buying an estimated $4.24M and bringing the position to 4,624,101 shares worth $83M. The position accounts for 11.91% of the portfolio, ranked #1.

Saturn V Capital Management first reported a position in AMLX in Q3 2023 and has held it in 9 quarters since. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Saturn V Capital Management held 4,624,101 shares of Amylyx Pharmaceuticals worth $83M as of Q2 2026.
Saturn V Capital Management bought 274,216 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $4.24M.
Amylyx Pharmaceuticals made up 11.91% of Saturn V Capital Management's portfolio in Q2 2026, its #1 holding.
Saturn V Capital Management first reported a position in Amylyx Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.